- Home
- MIRM vs ATHM Comparison
MIRM vs ATHM Comparison
Compare MIRM & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- ATHM
- Stock Information
- Founded
- MIRM 2018
- ATHM 2008
- Country
- MIRM United States
- ATHM China
- Employees
- MIRM N/A
- ATHM N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- ATHM EDP Services
- Sector
- MIRM Health Care
- ATHM Technology
- Exchange
- MIRM Nasdaq
- ATHM Nasdaq
- Market Cap
- MIRM 3.7B
- ATHM 3.3B
- IPO Year
- MIRM 2019
- ATHM 2013
- Fundamental
- Price
- MIRM $70.45
- ATHM $23.65
- Analyst Decision
- MIRM Strong Buy
- ATHM Hold
- Analyst Count
- MIRM 11
- ATHM 1
- Target Price
- MIRM $82.82
- ATHM $28.00
- AVG Volume (30 Days)
- MIRM 596.2K
- ATHM 328.4K
- Earning Date
- MIRM 11-04-2025
- ATHM 11-06-2025
- Dividend Yield
- MIRM N/A
- ATHM 10.34%
- EPS Growth
- MIRM N/A
- ATHM N/A
- EPS
- MIRM N/A
- ATHM 1.73
- Revenue
- MIRM $471,794,000.00
- ATHM $951,436,680.00
- Revenue This Year
- MIRM $53.14
- ATHM N/A
- Revenue Next Year
- MIRM $19.83
- ATHM $1.33
- P/E Ratio
- MIRM N/A
- ATHM $13.69
- Revenue Growth
- MIRM 53.66
- ATHM N/A
- 52 Week Low
- MIRM $36.88
- ATHM $23.14
- 52 Week High
- MIRM $78.55
- ATHM $32.70
- Technical
- Relative Strength Index (RSI)
- MIRM 50.06
- ATHM 32.53
- Support Level
- MIRM $68.60
- ATHM $23.11
- Resistance Level
- MIRM $73.02
- ATHM $24.17
- Average True Range (ATR)
- MIRM 3.10
- ATHM 0.68
- MACD
- MIRM 0.08
- ATHM -0.04
- Stochastic Oscillator
- MIRM 54.27
- ATHM 15.45
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About ATHM Autohome Inc.
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.